MX377525B - Composición farmacéutica oral de sales sulfato para comprimidos de uso dual y métodos para su uso. - Google Patents

Composición farmacéutica oral de sales sulfato para comprimidos de uso dual y métodos para su uso.

Info

Publication number
MX377525B
MX377525B MX2015012109A MX2015012109A MX377525B MX 377525 B MX377525 B MX 377525B MX 2015012109 A MX2015012109 A MX 2015012109A MX 2015012109 A MX2015012109 A MX 2015012109A MX 377525 B MX377525 B MX 377525B
Authority
MX
Mexico
Prior art keywords
oral pharmaceutical
dual
methods
pharmaceutical composition
sulfate salts
Prior art date
Application number
MX2015012109A
Other languages
English (en)
Other versions
MX2015012109A (es
Inventor
Edmund V Dennett Jr
David S Wells
Original Assignee
Braintree Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braintree Laboratories Inc filed Critical Braintree Laboratories Inc
Publication of MX2015012109A publication Critical patent/MX2015012109A/es
Publication of MX377525B publication Critical patent/MX377525B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D5/00—Sulfates or sulfites of sodium, potassium or alkali metals in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención generalmente se dirige a una composición para un comprimido farmacéutico oral que comprende una sal de sulfato, por ejemplo, sulfato de sodio, en donde la composición se puede administrar por ingestión oral directa y por desintegración en agua antes de la ingesta oral; la presente invención se dirige adicionalmente al uso de dichas formulaciones para un comprimido farmacéutico oral para inducir la laxación o para tratar o prevenir la constipación.
MX2015012109A 2013-03-15 2014-03-14 Composición farmacéutica oral de sales sulfato para comprimidos de uso dual y métodos para su uso. MX377525B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798759P 2013-03-15 2013-03-15
PCT/US2014/028805 WO2014144407A1 (en) 2013-03-15 2014-03-14 Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2015012109A MX2015012109A (es) 2016-04-15
MX377525B true MX377525B (es) 2025-03-10

Family

ID=50680164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012109A MX377525B (es) 2013-03-15 2014-03-14 Composición farmacéutica oral de sales sulfato para comprimidos de uso dual y métodos para su uso.

Country Status (25)

Country Link
US (2) US9919007B2 (es)
EP (2) EP3563838A1 (es)
JP (2) JP6441890B2 (es)
CN (2) CN108904462A (es)
AU (3) AU2014227598B2 (es)
BR (1) BR112015019776A2 (es)
CA (1) CA2903283C (es)
CY (1) CY1122387T1 (es)
DK (1) DK2968174T3 (es)
EA (2) EA034234B1 (es)
ES (1) ES2764462T3 (es)
HK (1) HK1214519A1 (es)
HR (1) HRP20192227T1 (es)
HU (1) HUE046754T2 (es)
IL (1) IL241367A0 (es)
LT (1) LT2968174T (es)
ME (1) ME03656B (es)
MX (1) MX377525B (es)
PE (1) PE20151543A1 (es)
PL (1) PL2968174T3 (es)
PT (1) PT2968174T (es)
RS (1) RS59667B1 (es)
SI (1) SI2968174T1 (es)
SM (1) SMT201900716T1 (es)
WO (1) WO2014144407A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014227598B2 (en) 2013-03-15 2018-12-06 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
WO2016040733A1 (en) * 2014-09-12 2016-03-17 Braintree Laboratories, Inc. Sulfate salt solution laxative compositions and methods of use thereof
US11007170B2 (en) 2017-02-02 2021-05-18 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
WO2022093170A1 (en) * 2020-10-26 2022-05-05 Braintree Laboratories, Inc. Sulfate salt formulations for colon cleansing
CN116509809B (zh) * 2023-04-19 2024-12-03 山东齐都药业有限公司 复方硫酸钠片剂及其制备方法与应用
US12239659B2 (en) 2023-06-15 2025-03-04 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873694A (en) 1973-09-27 1975-03-25 Cpc International Inc Direct compression tabletting composition and pharmaceutical tablets produced therefrom
JPS5438167B2 (es) 1974-04-27 1979-11-19
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2058565B (en) 1979-09-21 1983-12-07 Leo Pharm Prod Ltd Layer tablets
NZ198241A (en) 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3134591A1 (de) 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPS5839618A (ja) 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd 持続性積層錠剤
EP0080862B1 (en) 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS59101423A (ja) 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
JPS6097919A (ja) 1983-11-01 1985-05-31 Furointo Sangyo Kk 圧縮成形用賦形剤の製造方法
NL8400911A (nl) 1984-03-22 1985-10-16 Dagra Nv Werkwijze ter bereiding van een farmaceutische toedieningsvorm die tetracycline of doxycyclinezouten bevat.
JP2509594B2 (ja) 1985-08-01 1996-06-19 ブレインツリ−・ラボラトリ−ズ・インコ−ポレ−テッド 低ナトリウム緩下剤および洗浄剤処方
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
EP0281200B1 (en) 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
NO168563C (no) 1987-09-28 1992-03-11 Collett Marwell Hauge As Anvendelse av en organoleptisk akseptabel blanding av magnesiumsalter som mineraladditiv
JPH0194937A (ja) * 1987-10-06 1989-04-13 Yokohama Yushi Kogyo Kk 微粉状ミネラル類の被覆物の製造方法
US4837030A (en) 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5274001A (en) 1987-12-24 1993-12-28 Borody Thomas J Orthostatic lavage solutions
AU3367589A (en) 1988-04-05 1989-11-03 Dale Driver Dietary mineral sulfur supplement
JPH0816061B2 (ja) 1988-07-13 1996-02-21 森下ルセル株式会社 腸管洗浄液用組成物と腸管洗浄液
IT1229568B (it) 1989-04-17 1991-09-04 Giuliani Spa Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico.
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
DE69303813T2 (de) 1992-03-11 1997-01-16 The Procter & Gamble Co., Cincinnati, Ohio Gekörnte grundsätze enthaltende psyllium-getränkezusammenstellungen
MX9307359A (es) 1992-11-24 1994-06-30 Block Drug Co Composicion farmaceutica administrada oralmente, para el lavado gastrointestinal y metodo para su preparacion.
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5498425A (en) 1995-03-17 1996-03-12 Block Drug Company, Inc. Phosphosoda buffered saline laxative
US5710183A (en) 1995-07-14 1998-01-20 Halow; George M. Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
ATE235894T1 (de) 1996-05-08 2003-04-15 Craig A Aronchick Nichtwässrige abführmittel für den kolon
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
ES2202855T3 (es) 1997-04-18 2004-04-01 Janssen Pharmaceutica Nv Uso de antagonistas 5ht3 para promover el lavado intestinal.
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
JP2002528483A (ja) 1998-10-30 2002-09-03 マクニール−ピーピーシー・インコーポレイテッド 顆粒状で自由流動性の薬剤組成物、およびその経口投与のためのストロー状の投与形態
US6645481B1 (en) 2000-09-28 2003-11-11 Braintree Laboratories, Inc. Method of achieving overnight laxation and control of bowel function
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
AUPR590701A0 (en) 2001-06-25 2001-07-19 Colocaps Pty Ltd Laxative preparation
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US6946149B2 (en) 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
US20040071779A1 (en) 2002-10-09 2004-04-15 Keiser Dale Arthur Gelled laxative compositions
US7291324B2 (en) 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
GB0224909D0 (en) 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
SI1663257T1 (sl) 2003-07-09 2009-06-30 Braintree Lab Uporaba odvajal za zdravljenje sindroma razdraĺ˝ljivega äśrevesja
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
GB0409104D0 (en) * 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions
ATE476180T1 (de) 2004-06-04 2010-08-15 Braintree Lab Verfahren zur darmreinigung
WO2007013093A2 (en) 2005-04-01 2007-02-01 Shiv Prakash Laxative formulation containing a triphala extract
WO2006118562A1 (en) 2005-04-29 2006-11-09 Inkine Pharmaceutical Company, Inc. Purgative composition and uses thereof
EP1877039A4 (en) 2005-05-06 2010-08-18 Salix Pharmaceuticals Inc Polyethylene glycol GUT CLEANING COMPOSITION
US20070087056A1 (en) 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070082061A1 (en) 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
ATE506952T1 (de) 2005-12-29 2011-05-15 Braintree Lab Kits mit einem osmotischen laxans und einem stimulierenden laxans zur vorbereitung des kolon auf eine virtuelle kolonoskopie
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
WO2008141368A1 (en) 2007-05-17 2008-11-27 David Lubowski Combination laxative compositions comprising a colonic stimulant and a bulking laxative
JP2011500711A (ja) 2007-10-17 2011-01-06 トーマス・ジェファーソン・ユニバーシティ 腸の下剤およびその使用
EP2234482B1 (en) 2008-01-16 2015-08-05 Braintree Laboratories, Inc. Sulfate salt prophylaxis and therapies
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
ES2509892T3 (es) 2008-05-07 2014-10-20 Salix Pharmaceuticals, Ltd. Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal
US20100255122A1 (en) 2009-04-02 2010-10-07 Garren Mary L Edible gelatin bowel preparation and bowel cleansing method
AU2010239378B2 (en) 2009-04-21 2013-11-21 Dark Canyon Laboratories, Llc Colon lavage system
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
GB0912487D0 (en) 2009-07-17 2009-08-26 Norgine Bv Improvements in and relating to colon cleansing compositions
GB0913295D0 (en) 2009-07-30 2009-09-02 Norgine Bv Improvements in and relating to pharmaceutical compositions
US20130121916A1 (en) 2010-03-10 2013-05-16 Sergio Baroni Compositions for Colon Lavage and Methods of Making and Using Same
CA2795977A1 (en) 2010-03-12 2011-09-15 Scott Cordray Method of treatment
JP5665372B2 (ja) * 2010-06-02 2015-02-04 旭化成ケミカルズ株式会社 速崩壊性固形製剤
WO2012013928A1 (en) * 2010-07-27 2012-02-02 Norgine Bv Compositions
TWI520730B (zh) 2010-11-04 2016-02-11 諾金私人有限公司 調配物
CA2821196C (en) 2010-12-13 2022-11-22 Thomas Julius Borody Gastric and colonic formulations and methods for making and using them
WO2012091049A1 (ja) * 2010-12-28 2012-07-05 大鵬薬品工業株式会社 口腔内崩壊錠剤
CN105963701A (zh) 2011-01-28 2016-09-28 布伦特里实验室有限公司 用于肠道清洁的方法、组合物以及包装
KR101852502B1 (ko) 2011-01-31 2018-04-26 노어긴 비.브이. 조성물에 관한 개선
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
PL2696690T3 (pl) 2011-04-15 2018-03-30 Braintree Laboratories, Inc. Sole siarczanowe jako środek poprawiający czas przejścia
US8778907B2 (en) 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
US20140235730A1 (en) 2011-09-23 2014-08-21 Gavis Pharmaceuticals, Llc Solid, edible, chewable laxative composition
MX352891B (es) 2011-10-27 2017-12-13 Salix Pharmaceuticals Inc Purgantes electroliticos.
US9149493B2 (en) 2011-11-28 2015-10-06 Alfa Wassermann Spa Compositions for bowel cleansing and use thereof
AU2013308403B2 (en) 2012-08-29 2019-02-07 Salix Pharmaceuticals, Inc. Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
KR20170098980A (ko) 2012-09-11 2017-08-30 노어긴 비.브이. Peg 및 아스코르베이트를 포함하는 조성물
US20140087007A1 (en) 2012-09-27 2014-03-27 Braintree Laboratories, Inc. Bowel cleansing preparations
AU2014227598B2 (en) 2013-03-15 2018-12-06 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof

Also Published As

Publication number Publication date
US20180207200A1 (en) 2018-07-26
WO2014144407A8 (en) 2014-11-20
US20160030473A1 (en) 2016-02-04
ES2764462T3 (es) 2020-06-03
HUE046754T2 (hu) 2020-03-30
BR112015019776A2 (pt) 2017-07-18
IL241367A0 (en) 2015-11-30
EA201992382A2 (ru) 2020-02-28
CY1122387T1 (el) 2020-11-25
EP2968174B1 (en) 2019-10-16
RS59667B1 (sr) 2020-01-31
JP2016514677A (ja) 2016-05-23
PT2968174T (pt) 2020-01-15
DK2968174T3 (da) 2019-12-16
EP2968174A1 (en) 2016-01-20
AU2014227598A1 (en) 2015-08-27
PL2968174T3 (pl) 2020-05-18
EP3563838A1 (en) 2019-11-06
AU2019201511A1 (en) 2019-03-28
MX2015012109A (es) 2016-04-15
HK1214519A1 (zh) 2016-07-29
ME03656B (me) 2020-07-20
EA201992382A3 (ru) 2020-05-31
JP6724114B2 (ja) 2020-07-15
SMT201900716T1 (it) 2020-01-14
EA034234B1 (ru) 2020-01-20
AU2020213378A1 (en) 2020-08-27
SI2968174T1 (sl) 2020-02-28
HRP20192227T1 (hr) 2020-02-21
PE20151543A1 (es) 2015-11-29
AU2014227598B2 (en) 2018-12-06
JP2019023244A (ja) 2019-02-14
LT2968174T (lt) 2020-01-10
WO2014144407A1 (en) 2014-09-18
CA2903283A1 (en) 2014-09-18
CN108904462A (zh) 2018-11-30
CA2903283C (en) 2023-09-05
CN105142617A (zh) 2015-12-09
EA201591568A1 (ru) 2015-12-30
US9919007B2 (en) 2018-03-20
CN105142617B (zh) 2018-08-03
JP6441890B2 (ja) 2018-12-19

Similar Documents

Publication Publication Date Title
MX377525B (es) Composición farmacéutica oral de sales sulfato para comprimidos de uso dual y métodos para su uso.
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
PH12016502353A1 (en) Pharmaceutical composition
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
TW201613577A (en) Pharmaceutical combinations
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
UA115357C2 (uk) Похідні піридин-4-ілу
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2016000397A1 (es) Tratamiento contra el cáncer
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
GEP201706743B (en) Oral formulation for the treatment of cardiovascular diseases

Legal Events

Date Code Title Description
FG Grant or registration